JP2010508336A - IKK−βセリン−スレオニンプロテインキナーゼ阻害剤 - Google Patents

IKK−βセリン−スレオニンプロテインキナーゼ阻害剤 Download PDF

Info

Publication number
JP2010508336A
JP2010508336A JP2009535115A JP2009535115A JP2010508336A JP 2010508336 A JP2010508336 A JP 2010508336A JP 2009535115 A JP2009535115 A JP 2009535115A JP 2009535115 A JP2009535115 A JP 2009535115A JP 2010508336 A JP2010508336 A JP 2010508336A
Authority
JP
Japan
Prior art keywords
cyclopentyl
alkyl
carbamoyl
optionally substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009535115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508336A5 (enExample
Inventor
モファット,デビッド,フェストゥス,チャールズ
デイビス,スティーブン,ジョン
チャールトン,マイケル,ヒュー
ハースト,サイモン,クリストファー
オニオンズ,スチュアート,トーマス
ウィリアムス,ジョナサン,ガレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621720A external-priority patent/GB0621720D0/en
Priority claimed from GB0715470A external-priority patent/GB0715470D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of JP2010508336A publication Critical patent/JP2010508336A/ja
Publication of JP2010508336A5 publication Critical patent/JP2010508336A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009535115A 2006-11-01 2007-10-29 IKK−βセリン−スレオニンプロテインキナーゼ阻害剤 Withdrawn JP2010508336A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621720A GB0621720D0 (en) 2006-11-01 2006-11-01 Inhibitors of ikk- serine-threonine protein kinase
GB0715470A GB0715470D0 (en) 2007-08-09 2007-08-09 IKK- serine-threonine protein kinase inhibitors
PCT/GB2007/004114 WO2008053182A1 (en) 2006-11-01 2007-10-29 IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
JP2010508336A true JP2010508336A (ja) 2010-03-18
JP2010508336A5 JP2010508336A5 (enExample) 2010-12-16

Family

ID=39015937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535115A Withdrawn JP2010508336A (ja) 2006-11-01 2007-10-29 IKK−βセリン−スレオニンプロテインキナーゼ阻害剤

Country Status (15)

Country Link
US (1) US8003695B2 (enExample)
EP (1) EP2078007B1 (enExample)
JP (1) JP2010508336A (enExample)
KR (1) KR20090077975A (enExample)
AT (1) ATE522516T1 (enExample)
AU (1) AU2007315943A1 (enExample)
BR (1) BRPI0718056A2 (enExample)
CA (1) CA2668338A1 (enExample)
DK (1) DK2078007T3 (enExample)
EA (1) EA200900616A1 (enExample)
ES (1) ES2372707T3 (enExample)
IL (1) IL198267A0 (enExample)
MX (1) MX2009004442A (enExample)
NZ (1) NZ576705A (enExample)
WO (1) WO2008053182A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
US20110039920A1 (en) * 2008-04-23 2011-02-17 Chroma Therapeutics Ltd. Inhibitors of ikk-beta serine-theronine protein kinase
MX2010011643A (es) * 2008-04-26 2010-11-30 Chroma Therapeutics Ltd Tiofencarboxamidas sustituidas como inhibidores de la proteina cinasa ikk-beta serina, treonina.
US8470889B2 (en) * 2008-11-26 2013-06-25 Trt Pharma Inc. Hybrid-ionone and curcumin molecules as anticancer agents
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) * 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
KR20090077975A (ko) 2009-07-16
IL198267A0 (en) 2009-12-24
ATE522516T1 (de) 2011-09-15
EP2078007B1 (en) 2011-08-31
US20100087515A1 (en) 2010-04-08
DK2078007T3 (da) 2011-12-12
BRPI0718056A2 (pt) 2013-11-05
EP2078007A1 (en) 2009-07-15
WO2008053182A1 (en) 2008-05-08
NZ576705A (en) 2011-12-22
ES2372707T3 (es) 2012-01-25
EA200900616A1 (ru) 2010-04-30
US8003695B2 (en) 2011-08-23
CA2668338A1 (en) 2008-05-08
AU2007315943A1 (en) 2008-05-08
MX2009004442A (es) 2009-05-22

Similar Documents

Publication Publication Date Title
EP2078007B1 (en) Ikk-beta serine-threonine protein kinase inhibitors
JP2010508337A (ja) Ikk−ベータセリン−スレオニンプロテインキナーゼの阻害剤
KR101762574B1 (ko) 플라즈미노겐 액티베이터 인히비터-1 저해제
US20110190306A1 (en) Inhibitors of PLK
EP2079742A1 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
KR20090087013A (ko) 히스톤 탈아세틸효소의 억제제로서 히드록사메이트
JP5732408B2 (ja) 酵素阻害剤
JP2011518817A (ja) IKK−βセリン−、スレオニン−プロテインキナーゼ阻害剤としての置換されたチオフェンカルボキシアミド類
EP2297128B1 (en) Inhibitors of ikk- serine-threonine protein kinase
US7504431B2 (en) Sulfonyl amide inhibitors of calcium channel function
JP2012524767A (ja) Ikk−bセリン・スレオニンプロテインキナーゼのチオフェン阻害剤
CN101541779A (zh) IKK-β丝氨酸-苏氨酸蛋白激酶抑制剂
WO2009141575A1 (en) Inhibitors of plk

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101025

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120911